Frankfurt a.M. / Munich, November 10th, 2025. BioSpring, a world-leading CDMO for therapeutic oligonucleotide manufacturing and analysis, and metabion, a global leader in high-throughput manufacturing of high-quality custom oligonucleotides, are joining forces to help innovators advance the development of therapeutic oligonucleotides addressing unmet medical needs. metabion and BioSpring, both long-term specialized players in the field, will combine their expertise and capabilities to help drug developers move oligonucleotide programs into the clinic and beyond while significantly reducing timelines and costs, ensuring a streamlined development process.
In addition to their complementary CDMO manufacturing capacities and expertise in novel chemistry and modalities, both companies will leverage their respective nearly 30 years of experience in oligonucleotide manufacturing and analysis supporting drug developers from early discovery through commercialization. The combined capabilities and expertise span across the entire drug development life cycle, including: high-throughput manufacturing for candidate screening, bioanalytical services, preclinical through clinical and commercial manufacturing, all required analytical services, process validation and commercialization support, comprehensive regulatory services as well as companion diagnostics.
Dr. Regina Bichlmaier, CEO of metabion: “The collaboration allows early-stage innovators to begin with metabion’s focused support in candidate screening and lead discovery seamlessly moving to BioSpring as a partner for clinical and commercial manufacturing ensuring continuity, reliability, and speed from the start.”
Dr. Sylvia Wojczewski, CEO of BioSpring: “BioSpring and metabion joining forces creates a unique platform enabling oligonucleotide drug developers to make their life-changing treatments available to patients faster.”
metabion: metabion is a high-quality manufacturer of custom nucleic acids, focused on providing DNA/RNA oligonucleotides including customized solutions for R&D, diagnostic and therapeutic applications. The company is ISO 13485:2016 (equivalent to 21 CFR 820/cGMP Diagnostic), ISO 9001:2015 and EXCiPACT® GMP/GDP:2021 certified. 30 years of successfully translating the highest quality standard into daily practice is the key to deliver sustainable customer success.
metabion is located in Munich.
BioSpring: BioSpring is a globally leading contract manufacturer of oligonucleotides, with a strong focus on therapeutic oligonucleotides. Founded in 1997, the company partners with biotech and pharmaceutical companies worldwide throughout the entire drug development lifecycle, from early research to commercial manufacturing. BioSpring provides fully integrated manufacturing and analytical services for clinical (ICH Q7) and commercial programs. The company has been GMP-certified since 2007 and regularly FDA-inspected since 2016, underscoring its long-standing commitment to quality. In addition, BioSpring supports clients globally in producing oligonucleotides for research and diagnostic applications (ISO 13485- and ISO 9001-certified). The company is currently expanding its production capacities with a new, $150 million large-scale facility in Offenbach am Main to metric ton-annual capacity.
For more information, please contact us.